The purpose of this study is to evaluate the effect of Squill Oxymel in the patients with asthma. The study is a randomized, triple-blind and single-center which will be carried out on 51 patients with moderate to severe asthma referred to Imam Khomeini Hospital. Inclusion criteria include: age 18 to 50 years, treated with conventional medications and patients with moderate to severe asthma that was insufficiently controlled despite treatment with medium or high dose inhaled corticosteroids. Exclusion criteria include: add or remove the drugs that interfere with asthma (NSAIDs and corticosteroids) and infections leading to hospitalization. Method: with randomization (blocks), Patients will be divided into 3 groups of 17 people: Intervention Group 1 (Squill Oxymel, Oral Syrup, 10 ml twice a day), Intervention Group 2 (simple Honey Oxymel, Oral Syrup, 10 ml twice a day) and Control Group (placebo). Patients will be treated for 6 weeks. The Primary outcomes included quality of life and FEV1. Secondary outcomes included the FEV1 / FVC, RV, TLC, RV / TLC and RAW. These changes will be assessed with the quality of life questionnaires St. George (SGRQ), spirometry breathing test and wind box before and after the intervention.